ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SC rilvegostomig + rHu

Its studies are led by AstraZeneca.

Furthest: phase 1, since Sep 3, 20251 company-led study, 1 open or runningNext primary completion: Jul 19, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Sep 3, 2025Sep 3, 2025Jul 19, 2027phase 1 · NCT07161414

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2025First study: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyFirst studyNCT07161414 · 40 planned · United States, South Korea, Spain and more

Ahead

  1. Jul 19, 2027Primary completion: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT07161414

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07161414Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, South Korea, Spain and more1RecruitingJul 19, 202740

How it is read

Names in the registry

  • “SC rilvegostomig + rHu”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.